Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.
Novartis' multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical study.
Scientists believe a drug approved to treat multiple sclerosis may also be able to help prevent an unrelated medical condition--heart failure.
Novartis' multiple sclerosis drug Gilenya (fingolimod) could treat or even prevent colitis-associated cancer, if preclinical findings from U.S. researchers can be confirmed in later studies.
Novartis is gaining in emerging markets. It's also seeing growth in newly launched products, including a few potential blockbusters. Both very good things--and sorely needed to offset a manufacturing shutdown and eroding sales of its top-selling drug.
The Department of Defense has awarded a one-year grant to SRI International's bioscience division to develop an orally administered multiple sclerosis drug.
The drug dodged a bullet in the EU when the European Medicines Agency said it could remain on the market.
Expectations for the blockbuster status of Gilenya dimmed when Novartis disclosed that a patient taking the drug has developed a rare brain disease.
The Institute for Safe Medicine Practices has zeroed in on Novartis' new multiple sclerosis pill.
The U.K.'s cost-effectiveness watchdog has changed its mind about Gilenya. The National Institute for Health and Clinical Excellence at first rejected the Novartis multiple sclerosis pill, in spite of an up-front discount offer. Now, thanks to some new data from the Swiss drugmaker, NICE has decided to recommend the drug instead.